The BRAIN Act (H.R. 2767) packages several targeted steps to accelerate brain tumor research and improve care coordination for survivors. It requires public reporting of NIH‑funded brain tumor biospecimens, creates new NIH-supported research networks for glioblastoma and cellular immunotherapy, and funds outreach and pilot survivorship programs.
Those changes matter because they tackle three recurring bottlenecks: fragmented access to tissue and fluid samples, limited coordinated funding for high‑risk translational programs (including CAR‑T approaches), and low public and clinician awareness about clinical trials and biomarker testing. The bill combines information infrastructure, directed research dollars, provider/patient outreach, and an FDA guidance mandate to expand trial access for brain tumor patients.
At a Glance
What It Does
Requires entities holding NIH‑funded brain tumor biospecimens to report collection metadata to NIH for a searchable public locator; authorizes competitive NIH awards for a Glioblastoma Therapeutics Network and multi‑institutional CAR‑T team science projects; funds a national awareness campaign and demonstration projects about clinical trials and biomarker testing; creates survivorship pilot programs; and directs FDA to issue guidance within one year to reduce trial exclusions.
Who It Affects
Research institutions and biorepositories that hold NIH‑funded brain tumor specimens; academic medical centers and consortia that would apply for U‑series/U19 awards; community and specialty providers engaged in survivorship care; patients, caregivers, and clinicians targeted by the awareness campaign; and the FDA, which must publish guidance.
Why It Matters
The bill reduces information friction around sample access, channels dedicated dollars to high‑priority translational pipelines, and attempts to expand trial access and post‑treatment care. For compliance officers and research leaders, it creates new reporting obligations, specific funding opportunities, and potential enforcement risk tied to noncompliance with biospecimen reporting.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill defines a “covered biospecimen collection” as brain tumor tissue, cerebrospinal fluid, or other specimen types listed in the NCI Specimen Resource Locator when NIH funds were used to collect or acquire them. It authorizes NIH to maintain a searchable website (or integrate with an existing one) to publish the existence, location, descriptions, and contact information for these collections.
Entities holding NIH‑funded collections must report existing collections and new acquisitions to the NIH within statutory windows, and NIH may withhold funding from repeat or egregious violators.
To accelerate therapeutics, the bill creates two directed NIH programs. First, a Glioblastoma Therapeutics Network run through the U19 mechanism to shepherd agents from preclinical work into early‑phase human trials; Congress authorizes a substantial multi‑year appropriation for that network.
Second, a U‑series Team Science Award focused on brain tumor cellular immunotherapy (explicitly including CAR‑T) to support multi‑institutional preclinical and clinical work. The legislation requires a transition plan if an existing glioblastoma program is in place so the new program aligns with prior policies and procedures.On the outreach side, H.R. 2767 directs HHS to run a national campaign about cancer clinical trials and biomarker testing with written and digital materials, public service announcements, and targeted communications for high‑risk, rural, and underserved populations.
It also authorizes grants or contracts for demonstration projects that test outreach and education strategies; applicants with demonstrated expertise in biomarker testing, trial recruitment, working with patient groups, and reaching low‑participation geographies receive preference.For survivorship, the bill authorizes NIH pilot awards to eligible entities—medical schools, children’s hospitals, cancer centers, community facilities, and similar organizations—to develop, study, or evaluate models of lifelong monitoring and care coordination for adult and pediatric brain tumor survivors. Permitted activities include multidisciplinary care models, psychosocial supports, educational accommodations, peer programs, and tools (including AI‑enabled ones) to securely transfer treatment summaries and follow‑up plans.Finally, the bill requires FDA to issue guidance within one year identifying how to minimize the exclusion of brain tumor patients (and patients with rare or recalcitrant cancers) from clinical trials for other indications, with the goal of expanding appropriate trial access while preserving safety and scientific validity.
The Five Things You Need to Know
Entities holding NIH‑funded brain tumor biospecimens must report existing collections within 180 days of enactment and new collections within 60 days.
NIH must publish a searchable public locator for covered biospecimen collections and may withhold NIH funding from entities that repeatedly or egregiously fail to report.
Congress authorizes $50 million per year (FY2026–2030) for a Glioblastoma Therapeutics Network using the U19 mechanism to advance agents into early‑phase human trials.
The bill authorizes $10 million per year (FY2026–2030) for multi‑institutional U‑series awards to develop brain tumor cellular immunotherapies, explicitly including CAR‑T approaches.
The FDA must issue guidance within one year to reduce the inappropriate exclusion of brain tumor and other rare/recalcitrant cancer patients from clinical trials for other indications.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Findings and purposes
This section lays out Congress’s factual premise: stagnant survival for malignant brain tumors, a heavy pediatric burden, and a paucity of FDA‑approved treatments. Its operative purpose statements narrow the bill’s goals to strengthening research and improving awareness, adequacy, and access to specialized brain tumor care—language that constrains subsequent program design to research acceleration and access/outreach rather than broader health system reform.
Reporting of NIH‑funded brain tumor biospecimen collections
Defines ‘covered biospecimen collection’ and requires holders of NIH‑funded brain tumor specimens to submit metadata to NIH for a public, searchable listing. The clause differentiates existing collections (180‑day reporting window) from new ones (60 days) and directs NIH to set the specific data fields (at minimum matching NCI’s Specimen Resource Locator). Crucially, NIH’s oversight authority includes financial enforcement—repeated or egregious noncompliance can trigger withholding of NIH funds—creating an enforcement lever that research compliance offices must anticipate.
Glioblastoma Therapeutics Network and CAR‑T team science awards
Creates two distinct NIH award tracks: a U19‑based Glioblastoma Therapeutics Network to push promising agents from preclinical stages into early clinical trials, and a U‑series Team Science Award to coordinate multi‑institutional cellular immunotherapy (including CAR‑T) development for adult and pediatric brain tumors. Both tracks are explicitly authorized for multi‑year appropriations (specified dollar amounts per fiscal year through FY2030). The statute also requires NIH to transition any preexisting glioblastoma program into the new U19 structure in a manner consistent with existing policies, avoiding wholesale disruption of current trials while aligning new awards with established procedures.
National awareness campaign and demonstration projects on trials and biomarker testing
Directs HHS to run a coordinated national campaign that supplies written/digital materials, public service announcements, and public engagement to educate patients, caregivers, and clinicians about clinical trials and biomarker testing. Communications must be culturally and linguistically competent and target high‑risk, rural, and underrepresented populations. The section also funds demonstration grants to test outreach strategies, with preference for applicants experienced in biomarker testing, trial recruitment, patient engagement, and reaching low‑participation regions; awarded projects must tie together clinicians, health professional trainees, hospitals, and payers where possible.
Pilot programs for monitoring and caring for brain tumor survivors
Authorizes NIH to award pilot grants to eligible entities (medical schools, children’s hospitals, cancer centers, community facilities, and other experienced organizations) to develop and evaluate models of long‑term monitoring and care coordination across the lifespan. Approved activities include multidisciplinary care models, transition planning from specialty to primary care, psychosocial supports, educational accommodations, peer mentoring, and secure electronic transfer of treatment summaries—explicitly permitting use of AI/machine learning tools where appropriate. Awards must follow NIH peer review standards and prioritize geographic and size diversity among sites.
FDA guidance to limit exclusion of brain tumor patients from trials
Requires the FDA to issue guidance within 1 year identifying approaches to minimize unnecessary exclusion of brain tumor and other rare/recalcitrant cancer patients from clinical trials for different indications. The guidance is a non‑regulatory mechanism to encourage sponsors and IRBs to consider eligibility modifications where scientifically appropriate, balancing safety concerns against access. Its practical effect will depend on FDA’s framing and whether sponsors change protocol eligibility or engage in broader cohort models.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Adult and pediatric brain tumor patients and caregivers — through potentially faster development of new treatments, greater trial access when eligibility restrictions are reduced, improved information about biomarker testing, and pilot programs designed to improve long‑term follow‑up and quality of life.
- Academic and translational research consortia — the U19 and U‑series awards create dedicated, predictable funding streams for multi‑institutional glioblastoma and cellular immunotherapy programs that reduce the transactional friction of starting large collaborative trials.
- Biorepositories and researchers with NIH‑funded specimens — public listing increases discoverability and could lead to more collaborative use of scarce brain tumor tissue and fluids, improving sample utilization and hypothesis generation.
- Community providers and underserved populations — targeted outreach and the demonstration grants are designed to increase trial and biomarker testing awareness in rural and historically low‑participation communities, potentially widening the recruitment base for trials and access to precision diagnostics.
- Providers and institutions offering survivorship care — pilot funding supports development and dissemination of care‑coordination models, tools, and educational materials that can be adopted or adapted across systems.
Who Bears the Cost
- Research institutions and biorepositories — must compile and submit specimen metadata within statutory windows and may face funding sanctions for noncompliance; smaller repositories may need new staffing or systems to meet reporting requirements.
- NIH and HHS budgets — the bill authorizes multi‑year appropriations for networks, awards, outreach, and pilots; agencies will bear implementation costs and administrative overhead when appropriations are allocated.
- Clinical trial sponsors and protocol designers — FDA guidance aiming to broaden eligibility could require sponsors to rethink inclusion/exclusion criteria, add monitoring for neurological safety, or stratify analyses, increasing trial design complexity and potentially costs.
- Hospitals and clinics participating in pilots or demonstration projects — implementing multidisciplinary survivorship models, secure data transfer systems, or culturally competent outreach may require local investment in IT, staff training, and data governance.
- Institutional compliance and legal offices — increased public reporting and potential NIH enforcement raise compliance workload and legal exposure, including ensuring that specimen listing does not violate consent terms or privacy laws.
Key Issues
The Core Tension
The central dilemma is accelerating access to samples, trials, and post‑treatment care for a population with high unmet need while avoiding erosion of patient safety, privacy, and scientific rigor: greater inclusivity and transparency can speed discovery and access, but they also introduce risks—consent violations, increased trial heterogeneity, and uneven burdens on smaller institutions—that the bill does not fully resolve.
The bill’s biospecimen reporting increases transparency and discoverability but intersects with complex consent, privacy, and contractual regimes. Many collections were obtained under consent forms that limited downstream uses or public disclosure; research offices will have to reconcile statutory reporting requirements with existing consent language and state privacy laws.
NIH’s authority to withhold funds is an effective enforcement tool but risks disproportionately penalizing smaller or resource‑constrained repositories that lack the infrastructure to comply quickly.
Directed appropriations create focused incentives for glioblastoma and cellular immunotherapy research, but authorization is not the same as appropriations. The programs’ real impact depends on subsequent funding decisions and on how NIH designs U19/U‑series solicitations—scope, review criteria, and award size will determine whether the programs catalyze new multi‑site trials or simply repackage existing projects.
The FDA guidance is nonbinding; it may encourage broader eligibility but cannot compel sponsors to change protocols, and sponsors will weigh inclusivity against safety, heterogeneity, and regulatory risk. Finally, pilots that permit AI or machine learning tools for information transfer raise interoperability and validation challenges and may trigger additional HIPAA, FDA, or state oversight depending on their functions.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.